[High-dose chemotherapy and autologous bone marrow transplantation in solid tumors. A review].
This review deals with high-dose chemotherapy plus haematopoietic stem cell support as treatment to patients with chemosensitive solid tumours, breast-, testicular-, small cell lung-, and ovarian cancer. Dose-intensification of cytotoxic agents without stem cell support has not increased survival in these patients. High-dose chemotherapy plus stem cell support is a promising treatment strategy as adjuvant therapy in patients with high-risk breast cancer, i.e. more than 6-10 metastatic axillary lymph nodes, and there are several on-going randomized studies investigating conventional versus high-dose therapy in this situation both in Europe and in the US. Another international randomized study concerns patients with testicular cancer, where high-dose therapy is given as relapse treatment and as initial therapy in high-risk patients. High-dose therapy is an experimental treatment in all solid tumours, but there are no data supporting randomized studies in other solid tumours.
Handberg
J
J
Finsencentret, Onkologisk afdeling, Rigshospitalet, København.
Hansen
S W
SW
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation; D001943:Breast Neoplasms / Q000628:therapy; D018288:Carcinoma, Small Cell / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D013736:Testicular Neoplasms / Q000628:therapy; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents
Højdosis-kemoterapi med autolog knoglemarvstransplantation ved solide tumorer. En oversigt.